BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16699266)

  • 41. Serotonin and the GI tract.
    Hasler WL
    Curr Gastroenterol Rep; 2009 Oct; 11(5):383-91. PubMed ID: 19765366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical evaluation of a new preparation in upper digestive processes].
    Maldonado Eloy-García J; Escalante Llamas A; Ariza Moscoso A; Moreno López JM; Pérez Olivares J
    Rev Esp Enferm Apar Dig; 1974 Apr; 43(1):89-108. PubMed ID: 4840627
    [No Abstract]   [Full Text] [Related]  

  • 43. [Prokinetic agents (prokinetics) in the treatment of motor disorders of the gastrointestinal tract].
    Frol'kis AV
    Ter Arkh; 1998; 70(2):69-72. PubMed ID: 9551580
    [No Abstract]   [Full Text] [Related]  

  • 44. 5-HT receptors and visceral hypersensitivity - 2B or not 2B, that is the question?
    Grundy D
    Neurogastroenterol Motil; 2006 May; 18(5):339-42. PubMed ID: 16629859
    [No Abstract]   [Full Text] [Related]  

  • 45. Use of natural products in gastrointestinal therapies.
    Brierley SM; Kelber O
    Curr Opin Pharmacol; 2011 Dec; 11(6):604-11. PubMed ID: 21996284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Muscarinic agonists and antagonists: effects on gastrointestinal function.
    Ehlert FJ; Pak KJ; Griffin MT
    Handb Exp Pharmacol; 2012; (208):343-74. PubMed ID: 22222706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Promotility medications--now and in the future.
    Karamanolis G; Tack J
    Dig Dis; 2006; 24(3-4):297-307. PubMed ID: 16849857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational pharmacotherapy of gastrointestinal motility disorders.
    Demol P; Ruoff HJ; Weihrauch TR
    Eur J Pediatr; 1989 Apr; 148(6):489-95. PubMed ID: 2663504
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cisapride and other prokinetic agents in the treatment of gastroenterological diseases].
    Ryss ES; Fishzon-Ryss IuI
    Ter Arkh; 1995; 67(2):58-61. PubMed ID: 7725263
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapy of gastrointestinal motility disorders: moving in the right direction.
    Kuemmerle JF
    Gastroenterologist; 1994 Jun; 2(2):166-73. PubMed ID: 8055241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists.
    Sanger GJ; King FD
    Drug Des Deliv; 1988 Dec; 3(4):273-95. PubMed ID: 3076395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders.
    Sanger GJ; Lee K
    Nat Rev Drug Discov; 2008 Mar; 7(3):241-54. PubMed ID: 18309313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tachykinins and reflexly evoked atropine-resistant motility in the guinea pig colon in vivo.
    Giuliani S; Lecci A; Giachetti A; Maggi CA
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1224-31. PubMed ID: 8389857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tachykinin receptors and receptor subtypes.
    Patacchini R; Maggi CA
    Arch Int Pharmacodyn Ther; 1995; 329(1):161-84. PubMed ID: 7639617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prokinetic agents.
    Reynolds JC; Putnam PE
    Gastroenterol Clin North Am; 1992 Sep; 21(3):567-96. PubMed ID: 1516959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upper gastrointestinal promotility drugs: not all uniform?
    Brun R; Kuo B
    Indian J Gastroenterol; 2009; 28(4):123-5. PubMed ID: 19937420
    [No Abstract]   [Full Text] [Related]  

  • 57. Therapeutic approaches towards the treatment of gastroinstestinal disorders.
    Collingwood S; Witherington J
    Drug News Perspect; 2007 Mar; 20(2):139-44. PubMed ID: 17440638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peripheral tachykinin receptors as targets for new drugs.
    Patacchini R; Maggi CA
    Eur J Pharmacol; 2001 Oct; 429(1-3):13-21. PubMed ID: 11698023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approaches to the modulation of abdominal pain.
    Mayer EA; Lembo T; Chang L
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():65A-70A. PubMed ID: 10202211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders.
    Saito A; Alvi S; Valant C; Christopoulos A; Carbone SE; Poole DP
    Br J Pharmacol; 2024 Jul; 181(14):2232-2246. PubMed ID: 36565295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.